[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349425-105":59,"doc-detail-349425-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nat10-mediated-crosstalk-between-acetylation-and-parylation-enhances-the-function-of-parp1-promoting-primary-resistance-in-esophageal-cancer","NAT10-mediated crosstalk between acetylation and PARylation enhances the function of PARP1 promoting primary resistance in esophageal cancer","","Resistance to platinum-based drugs creates major clinical challenges for esophageal cancer, especially for patients showing primary resistance. This study shows NAT10 levels inversely correlate with the efficacy of platinum-based drug neoadjuvant therapy. Under oxaliplatin, NAT10 lowers oxaliplatin cytotoxicity while increasing invasion, migration, and clonogenic abilities. Mechanistically, oxaliplatin promotes NAT10 binding to PARP1, leading to PARP1 acetylation at K97 and enhanced PARylation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nat10-mediated-crosstalk-between-acetylation-and-parylation-enhances-the-function-of-parp1-promoting-primary-resistance-in-esophageal-cancer/349425/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nat10-mediated-crosstalk-between-acetylation-and-parylation-enhances-the-function-of-parp1-promoting-primary-resistance-in-esophageal-cancer/349425.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the study focus on?","Question",{"text":112,"@type":113},"The study addresses resistance to platinum-based drugs in esophageal cancer, with emphasis on primary resistance that leads to poor responses to initial therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does NAT10 affect esophageal cancer cells under oxaliplatin?",{"text":117,"@type":113},"In the presence of oxaliplatin, NAT10 reduces oxaliplatin cytotoxicity and increases esophageal cancer cells’ invasive, migratory, and clonogenic capabilities.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular mechanism links acetylation and PARylation in the study?",{"text":121,"@type":113},"Oxaliplatin promotes NAT10 binding to PARP1, after which NAT10 acetylates PARP1 at K97 to enhance PARP1 stability and increase PARylation, facilitating recruitment of downstream DNA repair proteins.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349425,1791189490,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cellular and Molecular Life Sciences (2026) 83:269  \n[https://doi.org/10.1007/s00018-026-06182-5](https://doi.org/10.1007/s00018-026-06182-5)  \nCellular and Molecular Life Sciences  \nORIGINAL ARTICLE  \nNAT10-mediated crosstalk between acetylation and PARylation enhances the function of PARP1 promoting primary resistance in esophageal cancer  \nYake Chen1 · Sizhen Hou1 · Boyuan Jiang1 · Yang Yang1 · Yisi Fan1 · Xinyue Huang1 · Fengxiang Liu1 · Wenjing An1 · Qiaocen Geng1 · Jie Yin1 · Huiqin Zheng1 · Kexin Guo1 · Ting Li1 · Wenwen Zhao1 · Zhijian Deng2,3 · Di Han1 · Heng Li4 · Yu Song1  \nReceived: 24 March 2025 / Revised: 21 October 2025 / Accepted: 18 December 2025 © The Author(s) 2026  \nAbstract  \nResistance to platinum-based drugs represents a significant challenge in the clinical treatment of esophageal cancer. Particularly, some esophageal cancer patients exhibit primary resistance to platinum-based drugs. Our study revealed that the level of N-acetyltransferase 10 (NAT10) is inversely correlated with the efficacy of platinum-based drug neoadjuvant therapy. In the presence of oxaliplatin, NAT10 significantly reduced the cytotoxicity of oxaliplatin and enhanced esophageal cancer cells’ invasive, migratory, and clonogenic abilities. Mechanistically, oxaliplatin promoted the binding of NAT10 to PARP1 . NAT10 acetylated PARP1 at the K97 site, thereby enhancing its stability. Additionally, acetylated PARP1 increased its PARylation modification, promoting the recruitment of downstream DNA repair proteins. In conclusion, NAT10 contributes to primary resistance by regulating the crosstalk of acetylation and PARylation of PARP1 in esophageal cancer.  \nKeywords Primary resistance · Esophageal cancer · Acetylation · PARylation · N-acetyltransferase 10  \nYake Chen and Sizhen Hou contributed equally to this work.  \n􀀍 Di Han [hd@xxmu.edu.cn](hd@xxmu.edu.cn)  \n􀀍 Heng Li[liheng@nus.edu.sg](liheng@nus.edu.sg)  \n􀀍 Yu Song [songyulab@xxmu.edu.cn](songyulab@xxmu.edu.cn)  \n1 Xinxiang Medical University, Xinxiang 453000, China  \n2 Department of Clinical Pharmacy, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China  \n3 Xinxiang Key Laboratory for Individualized Drug Use Research for Immune Diseases, Weihui 453100, China  \n4 Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456, Singapore  \nAbbreviations  \nESCA Esophageal cancer  \nGNAT Gcn5-related N-acetyltransferase  \nKD Knockdown  \nLIG1 DNA Ligase 1  \nL-OHP Oxaliplatin  \nNAM Nicotinamide NAT10 N-acetyltransferase 10  \nOE Overexpression  \nPTMs Protein post-translational modifications PARP1 poly (ADP-ribose) polymerase 1  \nTSA TrichostatinA  \nXRCC1 X-ray repair cross-complementing protein 1  \nIntroduction  \nEsophageal cancer (ESCA) ranks as the sixth leading cause of cancer-related deaths worldwide. Clinically, platinum-based antineoplastic agents, such as oxaliplatin, cisplatin, and carboplatin, are widely used in ESCA  \ntreatment. However, resistance to platinum-based drugs remains a critical factor contributing to clinical treatment failure [1, 2] . This resistance can be categorized as Primary or Acquired resistance [3, 4] . Primary resistance profoundly impacts ESCA patients’ responses to platinum-based chemotherapy and contributes to the variability in treatment outcomes following initial platinum-based drug administration [5] . The underlying mechanisms of Primary resistance remain unclear, which poses a significant challenge in treatment.  \nAcetylation modification is increasingly recognized as a key contributor to cancer chemoresistance [6–9] . NAT10 is a Gcn5-related N-acetyltransferase (GNAT) family member, including an acetyltransferase domain and a lysine-rich C-terminus [10] . It is involved in histone acetylation, telomerase activity regulation, DNA damage response, and cytokinesis [11–13] . Recent studies demonstrate that NAT10 plays diverse roles in cancer development and progression. For instance, NAT10 upregulation i","cbCaik5laXDCbn6Q","https://ap.wps.com/l/cbCaik5laXDCbn6Q","pdf",6416451,17,"English","# Abstract\n## Introduction\n## Materials and methods\n### Chemicals and reagents\n### Cell culture\n### Animals","[{\"question\":\"What clinical problem does the study focus on?\",\"answer\":\"The study addresses resistance to platinum-based drugs in esophageal cancer, with emphasis on primary resistance that leads to poor responses to initial therapy.\"},{\"question\":\"How does NAT10 affect esophageal cancer cells under oxaliplatin?\",\"answer\":\"In the presence of oxaliplatin, NAT10 reduces oxaliplatin cytotoxicity and increases esophageal cancer cells’ invasive, migratory, and clonogenic capabilities.\"},{\"question\":\"What molecular mechanism links acetylation and PARylation in the study?\",\"answer\":\"Oxaliplatin promotes NAT10 binding to PARP1, after which NAT10 acetylates PARP1 at K97 to enhance PARP1 stability and increase PARylation, facilitating recruitment of downstream DNA repair proteins.\"}]","NAT10-mediated crosstalk between acetylation and PARylation enhances the function of PARP1 promoting primary resistance in esophageal cancer | PDF",1790083270,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/987ab0555d96b56a67c6930a080c8d6e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b669b49fc84b4e7dc0a9a2db81c46d54.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf69388751e05d86be5bdbc92b9d6916.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e43284c8e093b7a37d35f2016fabf3ab.webp",980,1301]